Viking Therapeutics(US:VKTX) 智通财经网·2025-08-19 12:56Group 1 - Viking Therapeutics' experimental oral weight loss drug VK2735 showed disappointing mid-term trial data, leading to a nearly 34% pre-market drop in stock price [1] - VK2735 helped patients lose a maximum of 12.2% of their weight, but approximately 28% of participants dropped out of the trial within three months, raising concerns about its competitiveness against drugs from Eli Lilly and Novo Nordisk [1] - Eli Lilly's orforglipron trial results indicated an average weight loss of 12.4% over 72 weeks, which was below market expectations, as analysts had anticipated results similar to Novo Nordisk's Wegovy [1][2] Group 2 - The oral weight loss drug sector is viewed as a new frontier, but it presents significant scientific challenges for pharmaceutical companies [2] - Pfizer terminated its oral weight loss drug danuglipron development earlier this year due to liver damage signs in a clinical trial participant [2] - The perception of oral weight loss drug projects remains highly controversial on Wall Street [2]